سعر تيسينتريك 1200مجم فيال 2025

Atezolizumab 1200 mg/20 ml concentrate for intravenous infusion, 1 vial, by F. Hoffmann-La Roche; PD-L1-blocking monoclonal antibody for several cancers.

• Urothelial carcinoma (locally advanced or metastatic), as monotherapy in defined settingsPopulation: AdultsEuropean Medicines Agency (EPAR product information)
• Non-small cell lung cancer: adjuvant after resection (PD-L1 ≥50%), first-line metastatic (monotherapy or with chemotherapy/bevacizumab) and after prior chemotherapyPopulation: AdultsEuropean Medicines Agency (EPAR product information)
• Extensive-stage small cell lung cancer, first-line with carboplatin and etoposidePopulation: AdultsEuropean Medicines Agency (EPAR product information)

• Monotherapy (>10%): fatigue, decreased appetite, rash, nausea, cough, diarrhoea, pyrexia, dyspnoea, arthralgia, pruritus, asthenia, back pain, vomiting, urinary tract infection, headache.International label, same product · European Medicines Agency (EPAR product information)
• In combination (≥20%): anaemia, neutropenia, nausea, fatigue, alopecia, rash, diarrhoea, thrombocytopenia, constipation, decreased appetite, peripheral neuropathy.International label, same product · European Medicines Agency (EPAR product information)

• Hypersensitivity to atezolizumab or to any of the excipients.International label, same product · European Medicines Agency (EPAR product information)

• Immune-mediated adverse reactions (pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, myocarditis, skin and neurological reactions, among others) may occur; manage by withholding/discontinuing treatment and corticosteroids per SmPC guidance.International label, same product · European Medicines Agency (EPAR product information)
• Infusion-related reactions: reduce rate or interrupt for grade 1-2, permanently discontinue for grade 3-4.International label, same product · European Medicines Agency (EPAR product information)

• No human data; PD-L1/PD-1 pathway inhibition in animal models caused immune-mediated fetal rejection. Should not be used in pregnancy unless the clinical condition requires it; effective contraception during and for 5 months after treatment.International label, same product · European Medicines Agency (EPAR product information)
• Unknown whether excreted in human milk; a risk to the infant cannot be excluded; decide whether to stop breast-feeding or therapy.International label, same product · European Medicines Agency (EPAR product information)

• Atezolizumab: Binds PD-L1 and blocks its interaction with PD-1 and B7.1, releasing PD-L1/PD-1-mediated inhibition of the anti-tumour immune response.